<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113170</article-id><article-id pub-id-type="publisher-id">ACM-41086</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_14709170.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  影响
  <sub>P</sub>T
  <sub>2</sub>N
  <sub>0</sub>M
  <sub>0</sub>期胸段食管鳞癌术后失败的COX多因素分析结果及其对术后辅助治疗的指导意义
  Analysis of Postoperative Failure in Patients with Stage 
  <sub>P</sub>T
  <sub>2</sub>N
  <sub>0</sub>M
  <sub>0</sub> Esophageal Squamous Cell Carcinoma and Its Guiding Significance for Postoperative Adjuvant Therapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>有升</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>宏毅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>红杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陶</surname><given-names>鹤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沈</surname><given-names>文斌</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>河北医科大学第四医院放疗科，河北 石家庄</addr-line></aff><aff id="aff2"><addr-line>巴州人民医院放疗科，新疆 库尔勒</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1179</fpage><lpage>1186</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析
   <sub>P</sub>T
   <sub>2</sub>N
   <sub>0</sub>M
   <sub>0</sub>期胸段食管鳞癌术后患者的失败原因及其对术后辅助治疗的指导意义。方法：回顾性分析2007年1月至2010年12月在河北医科大学第四医院胸外科接受食管癌手术治疗的213例
   <sub>P</sub>
   T
   <sub>2</sub>
   N
   <sub>0</sub>
   M
   <sub>0</sub>期患者，分析其预后影响因素、失败原因等，应用SPSS19.0进行统计学分析，COX模型进行多因素分析。结果：全组出现胸腔内–区域复发54例(25.4%)，远处转移27例(12.7%)，胸腔内–区域复发合并远处转移患者15例。全组患者1、3、5年总生存率(OS)和无病生存率(DFS)分别为：93.9%、80.7%、71.7%和91.8%、77.3%、69.6%。COX多因素分析结果显示肿瘤组织分化程度为影响患者OS和DFS的独立性指标(P = 0.046、0.007)，另外病变部位也为影响患者DFS的独立性预后指标(P = 0.047)；食管病变部位为患者胸腔内–区域复发的独立性预后指标(P = 0.014)，肿瘤分化程度为影响远处转移的独立性预后指标(P = 0.021)。结论：即使接受了根治性手术切除的PT2N0M0期胸段食管鳞癌患者仍有较高的失败率，建议对于PT2N0M0期胸上段食管鳞癌和分化程度较低的患者应该积极予以术后辅助性治疗，最终结论需进行前瞻性研究证实。
    Objective: To analyze the causes of failure in PT2N0M0 thoracic esophageal squamous cell carcinoma postoperative patients and analyze the guiding significance of postoperative adjuvant radiotherapy. Methods: We retrospectively analyzed 213 patients with 
   <sub>P</sub>
   T
   <sub>2</sub>
   N
   <sub>0</sub>
   M
   <sub>0</sub> who underwent surgical treatment of esophageal cancer in our hospital from January 2007 to December 2010. The prognostic factors and failure reasons were analyzed. SPSS19.0 was used for statistical analysis, and COX model was used for multivariate analysis. Results: There were 54 cases (25.4%) with intrathoracic-regional recurrence in the whole group, 27 cases (12.7%) with distant metastases, and 15 cases with intrathoracic-regional recurrence and distant metastases. The overall survival (OS) and disease-free survival (DFS) of patients in the whole group were 93.9%, 80.7%, 71.7% and 91.8%, 77.3%, and 69.6%, respectively. Cox multivariate analysis showed that the degree of tumor differentiation was an independent index (P = 0.046, 0.007) that affected the OS and DFS of patients, and the location of lesions was also an independent prognostic index (P = 0.047); esophageal lesions were independent predictors of intrathoracic-regional recurrence (P = 0.014). The degree of tumor differentiation was an independent prognostic indicator of distant metastasis (P = 0.021). Conclusion: Even patients with 
   <sub>P</sub>
   T
   <sub>2</sub>
   N
   <sub>0</sub>
   M
   <sub>0</sub> thoracic esophageal squamous cell carcinoma undergoing radical resection have higher failure rate. It is recommended that postoperative adjuvant therapy should be actively performed for patients with 
   <sub>P</sub>
   T
   <sub>2</sub>
   N
   <sub>0</sub>
   M
   <sub>0</sub> upper thoracic esophageal squamous cell carcinoma and low differentiation. But, the final conclusion needs to be confirmed by forward-looking research. 
  
 
</p></abstract><kwd-group><kwd>食管肿瘤/食管癌，手术治疗，鳞癌，<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>，失败原因，COX多因素, Esophageal Neoplasms/Esophageal Cancer</kwd><kwd> Surgical Treatment</kwd><kwd> Squamous Cell Carcinoma</kwd><kwd> <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub></kwd><kwd> Cause of Failure</kwd><kwd> COX Multifactorial</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管鳞癌术后患者的失败原因及其对术后辅助治疗的指导意义。方法：回顾性分析2007年1月至2010年12月在河北医科大学第四医院胸外科接受食管癌手术治疗的213例<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期患者，分析其预后影响因素、失败原因等，应用SPSS19.0进行统计学分析，COX模型进行多因素分析。结果：全组出现胸腔内–区域复发54例(25.4%)，远处转移27例(12.7%)，胸腔内–区域复发合并远处转移患者15例。全组患者1、3、5年总生存率(OS)和无病生存率(DFS)分别为：93.9%、80.7%、71.7%和91.8%、77.3%、69.6%。COX多因素分析结果显示肿瘤组织分化程度为影响患者OS和DFS的独立性指标(P = 0.046、0.007)，另外病变部位也为影响患者DFS的独立性预后指标(P = 0.047)；食管病变部位为患者胸腔内–区域复发的独立性预后指标(P = 0.014)，肿瘤分化程度为影响远处转移的独立性预后指标(P = 0.021)。结论：即使接受了根治性手术切除的<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管鳞癌患者仍有较高的失败率，建议对于<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸上段食管鳞癌和分化程度较低的患者应该积极予以术后辅助性治疗，最终结论需进行前瞻性研究证实。</p></sec><sec id="s2"><title>关键词</title><p>食管肿瘤/食管癌，手术治疗，鳞癌，<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>，失败原因，COX多因素</p></sec><sec id="s3"><title>Analysis of Postoperative Failure in Patients with Stage <sub>p</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> Esophageal Squamous Cell Carcinoma and Its Guiding Significance for Postoperative Adjuvant Therapy</title><p>Yousheng Duan<sup>1</sup>, Hongyi Zhang<sup>1</sup>, Hongjie Yang<sup>1</sup>, He Tao<sup>1</sup>, Wenbin Shen<sup>2*</sup></p><p><sup>1</sup>Department of Radiation Oncology, Bazhou People’s Hospital, Kuerle Xinjiang</p><p><sup>2</sup>Department of Radiation Oncology, The Forth Hospital, Hebei Medical University, Shijiazhuang Hebei</p><p><img src="//html.hanspub.org/file/53-1572014x5_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/53-1572014x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the causes of failure in <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> thoracic esophageal squamous cell carcinoma postoperative patients and analyze the guiding significance of postoperative adjuvant radiotherapy. Methods: We retrospectively analyzed 213 patients with <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> who underwent surgical treatment of esophageal cancer in our hospital from January 2007 to December 2010. The prognostic factors and failure reasons were analyzed. SPSS19.0 was used for statistical analysis, and COX model was used for multivariate analysis. Results: There were 54 cases (25.4%) with intrathoracic-regional recurrence in the whole group, 27 cases (12.7%) with distant metastases, and 15 cases with intrathoracic-regional recurrence and distant metastases. The overall survival (OS) and disease-free survival (DFS) of patients in the whole group were 93.9%, 80.7%, 71.7% and 91.8%, 77.3%, and 69.6%, respectively. Cox multivariate analysis showed that the degree of tumor differentiation was an independent index (P = 0.046, 0.007) that affected the OS and DFS of patients, and the location of lesions was also an independent prognostic index (P = 0.047); esophageal lesions were independent predictors of intrathoracic-regional recurrence (P = 0.014). The degree of tumor differentiation was an independent prognostic indicator of distant metastasis (P = 0.021). Conclusion: Even patients with <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> thoracic esophageal squamous cell carcinoma undergoing radical resection have higher failure rate. It is recommended that postoperative adjuvant therapy should be actively performed for patients with <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> upper thoracic esophageal squamous cell carcinoma and low differentiation. But, the final conclusion needs to be confirmed by forward-looking research.</p><p>Keywords:Esophageal Neoplasms/Esophageal Cancer, Surgical Treatment, Squamous Cell Carcinoma, <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>, Cause of Failure, COX Multifactorial</p><disp-formula id="hanspub.41086-formula33"><graphic xlink:href="//html.hanspub.org/file/53-1572014x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/53-1572014x8_hanspub.png" /> <img src="//html.hanspub.org/file/53-1572014x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>手术治疗为早期食管癌主要治疗手段，但即使是接受了根治性手术的早期食管癌患者仍有较高的失败率，其中局部区域复发或和远处转移为其最主要的失败模式 [<xref ref-type="bibr" rid="hanspub.41086-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref3">3</xref>]。理论上认为放射治疗作为局部治疗手段可以在一定程度上降低局部区域复发率，化疗作为全身治疗的手段可以降低远处转移的发生率，但目前对早期食管癌术后患者是否应进行辅助放疗或和化疗缺乏循证医学证据，且目前对于<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管鳞癌(Thoracic esophageal squamous cell carcinoma, TESCC)术后失败的因素分析研究并不多见。因此，我们对在河北医科大学第四医院单中心接受治疗的<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期TESCC手术患者的失败原因进行了多因素分析，并依据治疗失败原因和既往相关文献进行有无进行术后辅助治疗必要性的讨论。</p></sec><sec id="s6"><title>2. 材料与方法</title><p>1) 入组标准：① 患者于我院胸外科接受行食管癌根治性手术切除术；② 术后病理证实为<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期，且为胸段食管鳞状细胞癌；③ 术前及术后未接受过新辅助或辅助性治疗。</p><p>2) 临床资料：对2007年1月至2010年12月在我院胸外科接受手术治疗并符合入组条件的213例食管癌患者进行回顾性，其中男性140例，女性73例；年龄41~79岁，中位61岁，其中≤60岁患者106例，&gt;60岁患者107例；胸上段26例，胸中段152例，胸下段35例；食管病变长度为1.0~12.0 cm，中位4.0 cm，其中病变长度 &lt; 5.0 cm患者129例，≥5.0 cm患者84例；术后病理为低分化鳞癌26例，中分化和高分化鳞癌187例；左侧胸腔入路198例，右侧胸腔入路15例；术中清扫淋巴结个数为5~32枚，中位10枚，其中清扫淋巴结数 &lt; 10枚患者112例，≥10枚患者101例；术后化疗91例，化疗方案主要为“替加氟注射液 + 顺铂”或“紫杉醇注射液 + 顺铂”，化疗周期数为1~6个，中位3个。</p><p>3) 术后失败诊断标准：失败部位及时间通过河北医科大学第四医院定期复查病例资料所确定，包括手术记录、影像学报告(CT、MRI及ECT等)、病理和细胞学的报告等。复发类型分为胸腔内–区域性失败和远处转移。</p><p>4) 术后淋巴结转移/复发诊断标准：依据日本食管疾病协会(JES)对复发淋巴结部位进行分区，包括双侧颈部及锁骨上区淋巴结、上纵膈区(胸上段食管旁和胸部气管旁)淋巴结、中纵膈区(气管隆突、胸中段气管 旁和肺门)淋巴结和下纵膈区(胸下段食管旁、横膈组、后纵膈)淋巴结，本研究将横膈以下归为腹腔淋巴结。浅表部位肿大淋巴结均经病理学证实；其余部位淋巴结均依据既往文献报道诊断标准，并联合CT扫描后显示的淋巴结大小、形状和融合状态等进行诊断。</p><p>5) 随访：随访截止至2015年12月31日，患者均按规律进行复查。复查项目主要包括：颈部和腹部超声，胸部强化CT/MR，部分患者行ECT和PET/CT检查。随访满1、3、5年者分别有200、172和152例，截止随访日期共死亡74例患者。</p><p>6) 统计方法：统计学分析采用SPSSl9.0软件进行，计数资料的比较采用X<sup>2</sup>检验，应用Kaplan-Meier法计算总生存率、复发率及远处转移率，并Log-rank法检验和单因素预后分析，Cox回归模型行多因素预后分析，检验水准α = 0.05。</p></sec><sec id="s7"><title>3. 结果</title><p>1) 患者失败模式分析结果：入组213例T2N0M0期胸段食管鳞癌根治术后患者，截止随访日期，出现胸腔内–区域复发54例，复发率为25.4%，复发时间为1.2~66.0个月，中位22.7个月，其中胸上段复发11例(42.3%)，胸中段复发38例(25.0%)，胸下段复发5例(14.3%)，依据卡方检验结果，不同病变部位患者的复发率存在著性差异(χ<sup>2</sup> = 6.225, P = 0.044)。不同病变部位的复发情况详见表1。从表1可见复发部位以纵膈淋巴结多见，其次为锁骨上区淋巴结，而腹腔淋巴结和吻合口复发发生率较低。胸上段累计出现纵膈淋巴结复发7例，其中上纵膈5例，中纵膈2例；胸中段累计出现纵膈淋巴结复发34例，其中上纵膈16例、中纵膈15例，余3例为下纵膈；胸下段累计出现纵膈淋巴结复发4例，其中下纵膈2例，中纵膈2例。</p><p>截止随访日期，出现远处转移27例，远处转移率为12.7%，远处转移出现时间为5.0~75.4个月，中位30.2个月，其中胸上段远处转移3例(11.5%)，胸中段远处转移18例(11.8%)，胸下段远处转移6例(16.7%)，依据卡方检验结果，不同病变部位的远处转移发生率差异未见显著性(χ<sup>2</sup> = 0.757, P = 0.685)。不同病变部位的远处转移情况详见表1，肺脏和肝脏为远处转移好发部位。胸腔内–区域复发合并远处转移患者15例。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Failure analysis of different lesion site</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >失败类型</th><th align="center" valign="middle"  colspan="3"  >病变部位</th></tr></thead><tr><td align="center" valign="middle" >胸上段</td><td align="center" valign="middle" >胸中段</td><td align="center" valign="middle" >胸下段</td></tr><tr><td align="center" valign="middle" >胸腔内–区域复发</td><td align="center" valign="middle" >锁上淋巴结复发2例 吻合口复发2例 纵膈淋巴结复发7例</td><td align="center" valign="middle" >锁上淋巴结复发2例 锁上和并纵膈淋巴结复发6例 纵膈淋巴结复发25例 吻合口合并中膈淋巴结复发3例 腹腔淋巴结复发2例</td><td align="center" valign="middle" >吻合口复发1例 纵膈淋巴结复发4例</td></tr><tr><td align="center" valign="middle" >远处转移</td><td align="center" valign="middle" >肺脏转移2例 多发转移1例</td><td align="center" valign="middle" >肺脏转移5例 骨转移5例 肝脏转移2例 肺脏合并肝脏转移1例 多发转移1例 其他部位转移4例</td><td align="center" valign="middle" >肺脏转移2例 肺脏合并肝脏转移1例 骨转移1例 多发转移2例</td></tr></tbody></table></table-wrap><p>表1. 不同病变部位失败情况分析结果</p><p>2) 影响患者预后的多因素分析结果：全组患者1、3、5年总生存率(OS)和无病生存率(DFS)分别为：93.9%、80.7%、71.7%和91.8%、77.3%、69.6%；中位值分别为77.8个月(95% CI: 73.045~82.544)和77.6个月(95% CI: 72.574~82.730)。将可能影响患者预后的因素进行COX多因素分析，其结果显示肿瘤组织分化程度为影响患者OS和DFS的独立性指标(P = 0.046, 0.007)，另外病变部位也为影响患者DFS的独立性预后指标(P = 0.047)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate analysis of prognostic factor</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >指标</th><th align="center" valign="middle"  rowspan="2"  >B</th><th align="center" valign="middle"  rowspan="2"  >SE</th><th align="center" valign="middle"  rowspan="2"  >Wald</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  rowspan="2"  >OB</th><th align="center" valign="middle"  colspan="2"  >95% CI</th></tr></thead><tr><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle" >OS</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >−0.434</td><td align="center" valign="middle" >0.268</td><td align="center" valign="middle" >2.625</td><td align="center" valign="middle" >0.105</td><td align="center" valign="middle" >0.648</td><td align="center" valign="middle" >0.383</td><td align="center" valign="middle" >1.095</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.228</td><td align="center" valign="middle" >0.180</td><td align="center" valign="middle" >1.608</td><td align="center" valign="middle" >0.205</td><td align="center" valign="middle" >1.256</td><td align="center" valign="middle" >0.883</td><td align="center" valign="middle" >1.788</td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" >−0.271</td><td align="center" valign="middle" >0.221</td><td align="center" valign="middle" >1.497</td><td align="center" valign="middle" >0.221</td><td align="center" valign="middle" >0.763</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >1.177</td></tr><tr><td align="center" valign="middle" >病变长度</td><td align="center" valign="middle" >−0.088</td><td align="center" valign="middle" >0.130</td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.499</td><td align="center" valign="middle" >0.916</td><td align="center" valign="middle" >0.709</td><td align="center" valign="middle" >1.182</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" >−0.591</td><td align="center" valign="middle" >0.307</td><td align="center" valign="middle" >3.702</td><td align="center" valign="middle" >0.046</td><td align="center" valign="middle" >0.629</td><td align="center" valign="middle" >0.388</td><td align="center" valign="middle" >1.018</td></tr><tr><td align="center" valign="middle" >清除淋巴结数目</td><td align="center" valign="middle" >−0.081</td><td align="center" valign="middle" >0.258</td><td align="center" valign="middle" >0.097</td><td align="center" valign="middle" >0.755</td><td align="center" valign="middle" >0.923</td><td align="center" valign="middle" >0.556</td><td align="center" valign="middle" >1.530</td></tr><tr><td align="center" valign="middle" >术后化疗</td><td align="center" valign="middle" >−0.354</td><td align="center" valign="middle" >0.258</td><td align="center" valign="middle" >1.876</td><td align="center" valign="middle" >0.171</td><td align="center" valign="middle" >0.702</td><td align="center" valign="middle" >0.423</td><td align="center" valign="middle" >1.165</td></tr><tr><td align="center" valign="middle" >DFS</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >−0.325</td><td align="center" valign="middle" >0.281</td><td align="center" valign="middle" >1.339</td><td align="center" valign="middle" >0.247</td><td align="center" valign="middle" >0.722</td><td align="center" valign="middle" >0.416</td><td align="center" valign="middle" >1.253</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.032</td><td align="center" valign="middle" >0.199</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >0.874</td><td align="center" valign="middle" >1.032</td><td align="center" valign="middle" >0.699</td><td align="center" valign="middle" >1.524</td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" >−0.470</td><td align="center" valign="middle" >0.237</td><td align="center" valign="middle" >3.928</td><td align="center" valign="middle" >0.047</td><td align="center" valign="middle" >0.625</td><td align="center" valign="middle" >0.393</td><td align="center" valign="middle" >0.995</td></tr><tr><td align="center" valign="middle" >病变长度</td><td align="center" valign="middle" >−0.076</td><td align="center" valign="middle" >0.143</td><td align="center" valign="middle" >0.286</td><td align="center" valign="middle" >0.593</td><td align="center" valign="middle" >0.926</td><td align="center" valign="middle" >0.700</td><td align="center" valign="middle" >1.226</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" >−0.832</td><td align="center" valign="middle" >0.309</td><td align="center" valign="middle" >7.247</td><td align="center" valign="middle" >0.007</td><td align="center" valign="middle" >0.435</td><td align="center" valign="middle" >0.237</td><td align="center" valign="middle" >0.798</td></tr><tr><td align="center" valign="middle" >清除淋巴结数目</td><td align="center" valign="middle" >−0.335</td><td align="center" valign="middle" >0.282</td><td align="center" valign="middle" >1.415</td><td align="center" valign="middle" >0.234</td><td align="center" valign="middle" >0.715</td><td align="center" valign="middle" >0.411</td><td align="center" valign="middle" >1.243</td></tr><tr><td align="center" valign="middle" >术后化疗</td><td align="center" valign="middle" >0.138</td><td align="center" valign="middle" >0.260</td><td align="center" valign="middle" >0.282</td><td align="center" valign="middle" >0.595</td><td align="center" valign="middle" >1.148</td><td align="center" valign="middle" >0.689</td><td align="center" valign="middle" >1.913</td></tr></tbody></table></table-wrap><p>表2. 患者预后影响指标的多因素分析结果</p><p>3) 影响患者失败的多因素分析结果：患者多因素分析结果显示食管病变部位胸腔内–区域复发的独立性预后指标(P = 0.014)，肿瘤分化程度为影响远处转移的独立性预后指标(P = 0.021)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Multivariate analysis of factors influencing intrathoracic regional recurrence and distant metastasi</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >指标</th><th align="center" valign="middle"  rowspan="2"  >B</th><th align="center" valign="middle"  rowspan="2"  >SE</th><th align="center" valign="middle"  rowspan="2"  >Wald</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  rowspan="2"  >OB</th><th align="center" valign="middle"  colspan="2"  >95% CI</th></tr></thead><tr><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle" >胸腔内–区域复发</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >−0.115</td><td align="center" valign="middle" >0.299</td><td align="center" valign="middle" >0.149</td><td align="center" valign="middle" >0.700</td><td align="center" valign="middle" >0.891</td><td align="center" valign="middle" >0.496</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.055</td><td align="center" valign="middle" >0.220</td><td align="center" valign="middle" >0.062</td><td align="center" valign="middle" >0.803</td><td align="center" valign="middle" >1.056</td><td align="center" valign="middle" >0.687</td><td align="center" valign="middle" >1.625</td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" >−0.640</td><td align="center" valign="middle" >0.261</td><td align="center" valign="middle" >6.008</td><td align="center" valign="middle" >0.014</td><td align="center" valign="middle" >0.527</td><td align="center" valign="middle" >0.316</td><td align="center" valign="middle" >0.88</td></tr><tr><td align="center" valign="middle" >病变长度</td><td align="center" valign="middle" >−0.182</td><td align="center" valign="middle" >0.165</td><td align="center" valign="middle" >1.227</td><td align="center" valign="middle" >0.268</td><td align="center" valign="middle" >0.833</td><td align="center" valign="middle" >0.603</td><td align="center" valign="middle" >1.151</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" >−0.761</td><td align="center" valign="middle" >0.482</td><td align="center" valign="middle" >2.490</td><td align="center" valign="middle" >0.115</td><td align="center" valign="middle" >0.467</td><td align="center" valign="middle" >0.182</td><td align="center" valign="middle" >1.202</td></tr><tr><td align="center" valign="middle" >清除淋巴结数目</td><td align="center" valign="middle" >−0.174</td><td align="center" valign="middle" >0.303</td><td align="center" valign="middle" >0.329</td><td align="center" valign="middle" >0.566</td><td align="center" valign="middle" >0.840</td><td align="center" valign="middle" >0.463</td><td align="center" valign="middle" >1.523</td></tr><tr><td align="center" valign="middle" >术后化疗</td><td align="center" valign="middle" >0.135</td><td align="center" valign="middle" >0.287</td><td align="center" valign="middle" >0.220</td><td align="center" valign="middle" >0.639</td><td align="center" valign="middle" >1.144</td><td align="center" valign="middle" >0.652</td><td align="center" valign="middle" >2.01</td></tr><tr><td align="center" valign="middle" >远处转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >−0.727</td><td align="center" valign="middle" >0.470</td><td align="center" valign="middle" >2.394</td><td align="center" valign="middle" >0.122</td><td align="center" valign="middle" >0.483</td><td align="center" valign="middle" >0.192</td><td align="center" valign="middle" >1.214</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >−0.047</td><td align="center" valign="middle" >0.319</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >0.884</td><td align="center" valign="middle" >0.955</td><td align="center" valign="middle" >0.511</td><td align="center" valign="middle" >1.783</td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" >0.198</td><td align="center" valign="middle" >0.366</td><td align="center" valign="middle" >0.291</td><td align="center" valign="middle" >0.589</td><td align="center" valign="middle" >1.219</td><td align="center" valign="middle" >0.594</td><td align="center" valign="middle" >2.499</td></tr><tr><td align="center" valign="middle" >病变长度</td><td align="center" valign="middle" >−0.009</td><td align="center" valign="middle" >0.218</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.967</td><td align="center" valign="middle" >0.991</td><td align="center" valign="middle" >0.646</td><td align="center" valign="middle" >1.521</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" >−0.800</td><td align="center" valign="middle" >0.347</td><td align="center" valign="middle" >5.324</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >0.450</td><td align="center" valign="middle" >0.228</td><td align="center" valign="middle" >0.887</td></tr><tr><td align="center" valign="middle" >清除淋巴结数目</td><td align="center" valign="middle" >−0.816</td><td align="center" valign="middle" >0.505</td><td align="center" valign="middle" >2.608</td><td align="center" valign="middle" >0.106</td><td align="center" valign="middle" >0.442</td><td align="center" valign="middle" >0.164</td><td align="center" valign="middle" >1.191</td></tr><tr><td align="center" valign="middle" >术后化疗</td><td align="center" valign="middle" >−0.230</td><td align="center" valign="middle" >0.419</td><td align="center" valign="middle" >0.301</td><td align="center" valign="middle" >0.583</td><td align="center" valign="middle" >0.795</td><td align="center" valign="middle" >0.349</td><td align="center" valign="middle" >1.806</td></tr></tbody></table></table-wrap><p>表3. 影响胸腔内–区域复发和远处转移指标的多因数分析结果</p></sec><sec id="s8"><title>4. 讨论</title><p>局部区域复发或和远处转移作为食管癌患者主要治疗失败模式，一直以来都是困扰临床医师的主要问题。本研究结果显示即使接受了根治性手术切除的<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期TSECC患者也有较高的复发率，一旦出现复发或和远处转移则预示患者预后严重不良，且他们为影响患者预后的唯一独立性指标。因此对于 pT<sub>2-3</sub>N<sub>0</sub>M<sub>0</sub>期TESCC同样有必要寻找其预后不良因素，早期识别预后好和预后不良的患者，以进行不同的术后干预，提高治疗水平。既往报道认为术后淋巴结阳性和局部病变较晚的食管癌患者可以从术后辅助治疗获益 [<xref ref-type="bibr" rid="hanspub.41086-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref6">6</xref>]，但对于<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期TSECC患者是否应该进行术后辅助性治疗？目前临床证据不足。Wang等 [<xref ref-type="bibr" rid="hanspub.41086-ref7">7</xref>] 人对326例接受了Ivor-Lewis手术的<sub>p</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期 ESCC患者进行了研究分析，他们将Ku80高表达患者随机分为辅助放疗组(106例)和对照组(106例)，未表达Ku80的124例为阴性组。结果显示对照组患者的OS和DFS差于阴性组(P &lt; 0.001, P &lt; 0.001)；放疗组与阴性组患者的OS和DFS无差异(P = 0.166, P = 0.648)；放疗组患者的OS和DFS显著优于对照组(P = 0.007, P &lt; 0.001)。多因素分析进一步提示，辅助放疗是Ku80过度表达患者的独立性预后指标，故他们认为Ku80可以作为预测<sub>p</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期ESCC患者的预测因子，且辅助放疗可显着提高Ku80过表达患者的存活率。Chen等 [<xref ref-type="bibr" rid="hanspub.41086-ref8">8</xref>] 对125例接受Ivor-Lewis手术的IIA期食管癌患者进行了研究，其中接受术后单纯放疗46例，接受系统化疗32例，18例患者接受了联合放化疗，另29例患者未接受任何治疗。结果显示局部区域复发率为26.4%，远处转移率为18.4%，术后放疗患者的局部区域复发率显著性低于其他组患者(P &lt; 0.05)，多因素分析结果显示术后辅助放疗为影响局部区域复发的独立性因素(P = 0.007)，他们认为接受Ivor-Lewis手术并两野淋巴结清除术患者联合术辅助放疗可能会使患者受益。</p><p>本研究对河北医科大学第四医院单中心213例<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期TSECC术后患者的治疗失败模式进行了分析，结果显示胸腔内–区域复发率为25.4%，远处转移率为12.7%。出现复发的部位主要为纵膈淋巴结，尤其是上纵膈淋巴结复发，其次为双侧锁骨上区的淋巴结复发，吻合口和腹腔淋巴结复发率较低，同时本研究表明复发发生率与患者病变部位显著相关，胸上段患者的复发率显著性高于胸中、下段食管癌患者。这可能与患者接受的手术方式有关，本研究中绝大多数患者接受的为“左胸入路的胸腹两野为主的淋巴结清扫术”的术式，此术式最大的弊端在于对于胸上段癌食管癌患者其手术视野限制、淋巴结清扫不够充分，但不影响胸中下癌食管癌患者的淋巴结清扫程度。食管癌第七版AJCC/UICC分期同样强调了肿瘤部位对患者预后影响的重要性。本研究结果显示病变部位为影响患者出现胸腔内–区域复发的独立性影响因素，Shi等 [<xref ref-type="bibr" rid="hanspub.41086-ref9">9</xref>] 对988例食管癌术后患者进行了分析，所有患者均未接受新辅助治疗或和术后辅助治疗，其中632例患者为pT<sub>2-3</sub>N<sub>0</sub>M<sub>0</sub>期，结果显示pT<sub>2-3</sub>N<sub>0</sub>M<sub>0</sub>期胸上、中及下段食管癌患者术后中位生存期分别为38.1、46.6和66.0个月，相应的5年生存率分别为40.0%、51.8%和66.2%，同时多因素分析表明肿瘤位置是pT2-3N0M0患者长期生存的重要独立预测因子。高玉华等 [<xref ref-type="bibr" rid="hanspub.41086-ref10">10</xref>] 分析了275例 pT<sub>2</sub>N<sub>0-1</sub>M<sub>0</sub>期胸段食管癌术后患者的临床资料，他们认为胸上段癌和<sub>P</sub>N<sub>1</sub>期患者的预后差，建议术后辅助治疗。刘晓等 [<xref ref-type="bibr" rid="hanspub.41086-ref11">11</xref>] 回顾分析581例食管癌术后患者，其中pT<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期153例、pT<sub>3</sub>N<sub>0</sub>M<sub>0</sub>期428例，接受单纯手术543例、术后放疗38例，他们认为pT<sub>2-3</sub>N<sub>0</sub>M<sub>0</sub>食管癌单纯手术后失败率较高，术后放疗可降低放疗部位失败率且提高DFS，但最终还需进一步加大样本量研究。综上，我们认为即使是接受了根治性手术的<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期TSECC患者仍有较高的胸腔内-区域复发率，建议此类患者可行术后放疗以降低胸腔内–区域复发率。</p><p>在食管癌的临床与基础研究中，分化程度作为食管癌重要的组织病理学指标受到重视。理论上认为肿瘤细胞分化程度越差，其恶性程度越高，瘤体生长较迅速，且易转移。但对于食管肿瘤分化程度是否影响患者预后目前结论不一 [<xref ref-type="bibr" rid="hanspub.41086-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref15">15</xref>]。Situ等 [<xref ref-type="bibr" rid="hanspub.41086-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref17">17</xref>] 人分别单独研究了<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>和<sub>P</sub>T<sub>3</sub>N<sub>0</sub>M<sub>0</sub>的食管鳞癌，在单纯<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>的胸段食管癌中，分化程度与预后相关，但在<sub>P</sub>T<sub>3</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管癌中，分化程度与预后无关。本研究结果显示肿瘤分化程度不影响患者的OS及DFS，但为患者远处转移的独立性预后影响指标。临床研究表明食管癌肿瘤分化程度与淋巴结转移密切相关 [<xref ref-type="bibr" rid="hanspub.41086-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref21">21</xref>]，相关报道 [<xref ref-type="bibr" rid="hanspub.41086-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.41086-ref23">23</xref>] 认为与高分化食管癌相比，中分化淋巴结转移度增加3倍，中低分化增加4.5倍，未分化增加6倍。因此，对于食管肿瘤分化程度应该予以更多的重视，辅助辅助性治疗是否对此部分患者有益值得进一步研究。</p><p>本研究的不足之处：本研究为回顾性，且为单中心资料，因此可能存在入选病例的偏倚性；本研究入组时间较为长，手术方式多数为左侧开胸，且清扫淋巴结数目较少，可能会影响本研究的研究结果。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，即使接受了根治性手术切除的<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管鳞癌患者仍有较高的失败率，依据既往相关文献研究结果和本研究结果，我们建议对于<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸上段食管鳞癌和分化程度较低的患者应该积极予以术后辅助性治疗，但最终结论需要进行前瞻性大宗病例证实。</p></sec><sec id="s10"><title>声明</title><p>本研究获省部共建中亚高发病成因与防治国家重点实验室开放课题项目《胸段食管鳞癌患者根治性同步放化疗中不同放疗剂量疗效比较的Ⅲ期随机对照临床研究》基金支持，项目编号：SKL-HIDCA-2020-39。</p><p>本研究已获得病人知情同意。</p></sec><sec id="s11"><title>文章引用</title><p>段有升,张宏毅,杨红杰,陶 鹤,沈文斌. 影响<sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>期胸段食管鳞癌术后失败的COX多因素分析结果及其对术后辅助治疗的指导意义Analysis of Postoperative Failure in Patients with Stage <sub>P</sub>T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> Esophageal Squamous Cell Carcinoma and Its Guiding Significance for Postoperative Adjuvant Therapy[J]. 临床医学进展, 2021, 11(03): 1179-1186. https://doi.org/10.12677/ACM.2021.113170</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41086-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Berry, M.F., Zeyer-Brunner, J., Castleberry, A.W., et al. (2013) Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy versus Surgical Resection. Journal of Thoracic Oncology, 8, 796-802.  
://doi.org/10.1097/JTO.0b013e3182897bf1</mixed-citation></ref><ref id="hanspub.41086-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Martin, J.T., Worni, M., Zwischenberger, J.B., et al. (2013) The Role of Radiation Therapy in Resected T2N0 Esophageal Cancer: A Population-Based Analysis. The Annals of Thoracic Surgery, 95, 453-458.  
://doi.org/10.1016/j.athoracsur.2012.08.049</mixed-citation></ref><ref id="hanspub.41086-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shen, W.B., Zhu, S.C., Gao, H.M., et al. (2016) Analysis of Failure Patterns in Patients with Resectable Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy. Journal of Cancer Research and Therapeutics, 12, 62-68.  
://doi.org/10.4103/0973-1482.146128</mixed-citation></ref><ref id="hanspub.41086-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Matsuda, S., Takeuchi, H., Kawakubo, H., et al. (2016) Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Annals of Thoracic and Cardiovascular Surgery, 22, 275-283. ://doi.org/10.5761/atcs.ra.16-00111</mixed-citation></ref><ref id="hanspub.41086-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, Z.F., Yang, Z.Y., Miao, Y.J., et al. (2005) Influence of Number of Metastatic Lymph Nodes on Survival of Curative Resected Thoracic Esophageal Cancer Patients and Value of Radiotherapy: Report of 549 Cases. International Journal of Radiation Oncology • Biology • Physics, 62, 82-90. ://doi.org/10.1016/j.ijrobp.2004.08.046</mixed-citation></ref><ref id="hanspub.41086-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J.Q., Pan, J.J., Zheng, X.W., et al. (2012) Number and Location of Positive Nodes, Postoperative Radiotherapy, and Survival after Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology • Biology • Physics, 82, 475-482.  
://doi.org/10.1016/j.ijrobp.2010.08.037</mixed-citation></ref><ref id="hanspub.41086-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Wang, Z., Yang, Z., et al. (2016) Postoperative Radiotherapy Improves Survival in Stage pT2N0M0 Esophageal Squamous Cell Carcinoma with High Risk of Poor Prognosis. Annals of Surgical Oncology, 23, 265-272.  
://doi.org/10.1245/s10434-015-4622-0</mixed-citation></ref><ref id="hanspub.41086-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, G., Wang, Z., Liu, X.Y., et al. (2009) Clinical Study of Modified Ivor-Lewis Esophagectomy plus Adjuvant Radiotherapy for Local Control of Stage IIA Squamous Cell Carcinoma in the Mid-Thoracic Esophagus. European Journal of Cardio-Thoracic Surgery, 35, 1-7. ://doi.org/10.1016/j.ejcts.2008.09.002</mixed-citation></ref><ref id="hanspub.41086-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shi, H., Zhang, K., Niu, Z.X., et al. (2015) Does Tumour Location Influence Postoperative Long-Term Survival in Patients with Oesophageal Squamous Cell Carcinoma? European Journal of Cardio-Thoracic Surgery, 48, 266-272.  
://doi.org/10.1093/ejcts/ezv006</mixed-citation></ref><ref id="hanspub.41086-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">高玉华, 王玉祥, 李静, 等. 影响pT2N0~1M0期胸段食管癌患者术后疗效的因素分析[J]. 中华肿瘤杂志, 2017, 39(9): 683-688.</mixed-citation></ref><ref id="hanspub.41086-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">沈文斌, 高红梅, 祝淑钗, 等. pT3N0M0期胸段食管鳞癌患者术后失败原因分析及其术后放疗思考[J]. 中华放射肿瘤学杂志, 2017, 26(4): 394-399.</mixed-citation></ref><ref id="hanspub.41086-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.B., Weng, H.R., Wang, G., et al. (2013) Prognostic Factors and Outcome for Patients with Esophageal Squamous Cell Carcinoma Underwent Surgical Resection Alone: Evaluation of the Seventh Edition of the American Joint Committee on Cancer Staging System for Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 8, 495-501. ://doi.org/10.1097/JTO.0b013e3182829e2c</mixed-citation></ref><ref id="hanspub.41086-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ma, G., Zhang, X., Ma, Q., et al. (2015) A Novel Multivariate Scoring System for Determining the Prognosis of Lymph Node-Negative Esophageal Squamous Cell Carcinoma Following Surgical Therapy: An Observational Study. European Journal of Surgical Oncology, 41, 541-547. ://doi.org/10.1016/j.ejso.2015.01.013</mixed-citation></ref><ref id="hanspub.41086-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Wu, N., Zheng, Q.F., et al. (2014) Evaluation of the 7th Edition of the TNM Classification in Patients with Resected Esophageal Squamous Cell Carcinoma. World Journal of Gastroenterology, 20, 18397-18403.  
://doi.org/10.3748/wjg.v20.i48.18397</mixed-citation></ref><ref id="hanspub.41086-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Y., Liu, J., Du, X., et al. (2013) Prognostic Impact of Postoperative Radiation in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Cancer. Radiation Oncology, 8, Article No. 116.  
://doi.org/10.1186/1748-717X-8-116</mixed-citation></ref><ref id="hanspub.41086-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Situ, D., Wang, J., Lin, P., et al. (2013) Do Tumor Location and Grade Affect Survival in pT2N0M0 Esophageal Squamous Cell Carcinoma? Journal of Thoracic and Cardiovascular Surgery, 146, 45-51.  
://doi.org/10.1016/j.jtcvs.2013.01.034</mixed-citation></ref><ref id="hanspub.41086-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Situ, D., Wei, W., Lin, P., et al. (2013) Do Tumor Grade and Location Affect Survival in Esophageal Squamous Cell Carcinoma? Survival Analysis of 302 Cases of pT3N0M0 Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 20, 580-585. ://doi.org/10.1245/s10434-012-2656-0</mixed-citation></ref><ref id="hanspub.41086-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">王玉祥, 董石磊, 何明, 等. pT1-3N0M0期食管鳞癌二野术后复发和转移的因素分析[J]. 中华放射肿瘤学杂志, 2018, 27(2): 145-149.</mixed-citation></ref><ref id="hanspub.41086-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王玉祥, 王丽丽, 李静, 等. T3N0M0期胸段食管鳞癌术后复发或转移的挽救治疗分析[J]. 中华放射肿瘤学杂志, 2016, 25(10): 1070-1073.</mixed-citation></ref><ref id="hanspub.41086-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Deng, F., Liu, Q. and Ma, Y. (2017) Prognostic Significance of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Pathology—Research and Practice, 213, 842-847.  
://doi.org/10.1016/j.prp.2017.01.023</mixed-citation></ref><ref id="hanspub.41086-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Rice, T.W., Ishwaran, H., Hofstetter, W.L., et al. (2017) Esophageal Cancer: Associations with (pN+) Lymph Node Metastases. Annals of Surgery, 265, 122-129. ://doi.org/10.1097/SLA.0000000000001594</mixed-citation></ref><ref id="hanspub.41086-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">吴彬, 徐志飞, 孙耀昌, 等. 食管癌的侵犯深度及分化程度与区域淋巴结转移的关系[J]. 第二军医大学学报, 2000, 21(8): 771-773.</mixed-citation></ref><ref id="hanspub.41086-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">李国仁, 戴建华. 食管癌淋巴结转移研究状况及其治疗策略[J]. 中国肿瘤, 2007, 6(11): 915-919.</mixed-citation></ref></ref-list></back></article>